Prospective Randomized, Double-blind, Parallel-controlled Versus Placebo in a Polyvalent Sublingual Bacterial Vaccine to 3 Months and 6 Months in Women With RUTI for the Immunomodulatory Efficacy Evaluation, Safety and Clinical Impact
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2018
At a glance
- Drugs MV 140 (Primary)
- Indications Urinary tract infections
- Focus Therapeutic Use
- Sponsors Inmunotek
- 02 Mar 2017 Planned End Date changed from 1 Jan 2019 to 1 Dec 2019.
- 02 Mar 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 22 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.